Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 14/20 | 0.75 |
| ▸ | MAOA known ✓ | P21397 | 12/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 13/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.75 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.75 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL5070770 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL40650 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL4332273 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL5075069 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL5070768 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL13764364 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL1720497 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL4740285 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL1649712 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL3406205 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024233765-A1 | THERAPEUTIC APPROACH TO BLOCK TERMINAL EXHAUSTION OF T CELLS AND SYNERGIZE THE EFFICACY OF T CELL IMMUNOTHERAPIES | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240418723-A1 | SEQUENTIAL TREATMENTS AND BIOMARKERS TO REVERSE RESISTANCE TO KINASE INHIBITORS | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2024-12-19 | — | — | US | disclosed |
| WO-2024233765-A1 | THERAPEUTIC APPROACH TO BLOCK TERMINAL EXHAUSTION OF T CELLS AND SYNERGIZE THE EFFICACY OF T CELL IMMUNOTHERAPIES | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-116077661-B | Application of KDM1A inhibitor in preparation of medicine for treating DNMT3A gene deletion cancer | 沈阳药科大学 | 2024-09-27 | — | — | CN | disclosed |